🏛️ Verified NIH Record • Updated 2025-12-23
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD (NCT04580420)
A Phase 2 Open-Label Study to Evaluate the Safety and Efficacy of DCR-PHXC in Patients With Primary Hyperoxaluria Type 1 and Severe Renal Impairment, With or Without Dialysis
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
🩺 Plain-English Summary (8th-Grade Level)
The aim of this study is to evaluate DCR-PHXC in participants with PH1 and severe renal impairment, with or without dialysis.
Who can join: Review the eligibility criteria below.
Location: Clinical Trial Site — San Francisco, California
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Clinical Trial Site — San Francisco, California
- Clinical Trial Site — Boston, Massachusetts
- Clinical Trial Site — Rochester, Minnesota
- Clinical Trial Site — New York, New York
- Clinical Trial Site — Bron,
- Clinical Trial Site — Paris,
- Clinical Trial Site — Bonn,
- Clinical Trial Site — Heidelberg,
- Clinical Trial Site — Roma,
- Clinical Trial Site — Beirut,
- Clinical Trial Site — Casablanca,
- Clinical Trial Site — Oradea,
- Clinical Trial Site — Oradea,
- Clinical Trial Site — Barcelona,
- Clinical Trial Site — Santa Cruz de Tenerife,
- Clinical Trial Site — Dubai,
- Clinical Trial Site — London,
- Clinical Trial Site — London,
📞 Contact the Study Coordinator
Phone: (866) 867-7178
Email: clinicaltrials@novonordisk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Primary Hyperoxaluria Type 1
Explore by condition: All Primary Hyperoxaluria Type 1 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.